|
|
 = Add Release to Briefcase |
| All Releases |
|---|
 |
Affymax(R) Reports First Quarter 2008 Financial Results
May 9, 2008
|
10.5 KB
|
| |
PALO ALTO, Calif., May 09, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the first quarter ended March 31, 2008. The net loss for the first quarter of 2008 was $15.6 million compared to a net loss of $7.2 million for the first quarter of 2007.
Affymax recognized revenue for the quarter ended March 31, ...
|
|
|
Affymax Announces Upcoming Webcasts and Conference Participation
Apr 22, 2008
|
6.0 KB
|
| |
PALO ALTO, Calif., Apr 22, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that Arlene Morris, the company's president and chief executive officer, will present at the following investor conferences in April and May.
Morgan Stanley Global Healthcare Unplugged Conference
The Ritz-Carlton, Key Biscayne, Fla.
Wednesday, Apr...
|
|
|
Affymax Appoints Vice President, Biostatistics and Data Management
Apr 14, 2008
|
6.9 KB
|
| |
PALO ALTO, Calif., Apr 14, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced the appointment of Carol Francisco, Ph.D. as vice president, Biostatistics and Data Management. Dr. Francisco, who has more than 20 years of biostatistics and data management experience, joins Affymax as a member of the senior management team reporting to...
|
|
|
Affymax and Takeda Report Long-Term Safety and Effectiveness Data of Hematide in Chronic Renal Failure Patients With Anemia
Apr 4, 2008
|
9.2 KB
|
| |
DALLAS, Apr 04, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) and Takeda Global Research & Development today announced data from their ongoing Phase 2 trial to assess the long-term safety and tolerability of Hematide(TM), a potential treatment of anemia. These data showed that Hematide, dosed once every four weeks, successfully maintained mea...
|
|
|
Affymax(R) Reports Year End 2007 Financial Results
Mar 13, 2008
|
11.4 KB
|
| |
PALO ALTO, Calif., Mar 13, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the year ended December 31, 2007. The net loss for the year 2007 was $43.1 million compared to a net loss of $48.3 million for the year ended December 31, 2006.
Affymax recognized revenue for the year ended December 31, 2007 of $4...
|
|
|
Affymax to Present at Cowen and Company's 28th Annual Health Care Conference
Mar 10, 2008
|
5.8 KB
|
| |
PALO ALTO, Calif., Mar 10, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that Jeffrey H. Knapp, the company's chief commercial officer, will present at Cowen and Company's 28th Annual Health Care Conference on Monday, March 17, 2008, at 11:30 a.m. ET at The Boston Marriott Copley Place.
A live webcast of the presentation w...
|
|
|
Affymax Affirms Progress with Takeda Collaboration
Feb 5, 2008
|
6.8 KB
|
| |
PALO ALTO, Calif., Feb 05, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today affirmed its ongoing collaboration with Takeda Pharmaceutical Company Limited for the global development and commercialization of Hematide(TM), Affymax's lead product candidate for the treatment of anemia, continues to progress as planned.
"Our partnership is u...
|
|
|
Affymax to Present at BIO CEO & Investor Conference
Feb 5, 2008
|
5.8 KB
|
| |
PALO ALTO, Calif., Feb 05, 2008 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq: AFFY) today announced that Arlene Morris, the company's president and chief executive officer, will present at the 10th Annual BIO CEO & Investor Conference on Wednesday, February 13, 2008, at 12:30 p.m. ET at the Waldorf-Astoria in New York City.
A live webcast of the pr...
|
|
|
Takeda Doses First Patient In A U.S. Phase 1 Study Of Hematide™ To Treat Chemotherapy Induced Anemia
Jan 25, 2008
|
8.7 KB
|
| |
OSAKA, Japan (Jan-25) and PALO ALTO, Calif. (Jan-24), 2008 - Takeda Pharmaceutical Company Limited (TSE: 4502) and Affymax, Inc. (Nasdaq: AFFY) today announced that Takeda has dosed the first patient in the United States in a clinical trial of the investigational new drug, Hematide™, for the treatment of anemia in cancer patie...
|
|
|
Affymax Appoints Keith Leonard and Christi van Heek to its Board of Directors
Dec 10, 2007
|
8.1 KB
|
| |
PALO ALTO, Calif., Dec 10, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced the appointment of Keith Leonard and Christi van Heek to the company's board of directors. Mr. Leonard has nearly 20 years of operations experience at biotechnology companies, including 13 years at Amgen, Inc. Ms. van Heek's 25 years in the healthcare and...
|
|
|
The press releases may contain historical information and may no longer be accurate. Affymax disclaims any responsibility to update such information.
|
